Comparison of lentiviral and adenoviral gene therapy for spinal fusion in rats

Spine

Volumn 33, Issue 13, 2008, Pages 1410-1417

  Miyazaki, Masashi ^a   Sugiyama, Osamu ^b   Zou, Jun ^a   Yoon, Seung Hwan ^a   Wei, Feng ^a   Morishita, Yuichiro ^a   Sintuu, Chananit ^a   Virk, Mandeep S ^b   Lieberman, Jay R ^b   Wang, Jeffrey C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Bone morphogenetic protein; Gene therapy; Lentivirus; Rat model; Spine fusion

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; COLLAGEN SPONGE; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE REMODELING; CONTROLLED STUDY; GENE TRANSFER; GENETIC TRANSFECTION; IMPLANTATION; INTERMETHOD COMPARISON; LEWIS RAT; LUMBAR SPINAL CORD; MALE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; PALPATION; PRIORITY JOURNAL; PSEUDARTHROSIS; RAT; SPINE; SPINE FUSION; VERTEBRA; VIRAL GENE THERAPY; VIRUS GENE; ADENOVIRUS; ANIMAL; BONE DEVELOPMENT; BONE MARROW TRANSPLANTATION; CELL CULTURE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LENTIVIRINAE; LUMBAR VERTEBRA; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

ADENOVIRIDAE; ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; GENE THERAPY; GENETIC VECTORS; LENTIVIRUS; LUMBAR VERTEBRAE; MALE; MODELS, ANIMAL; OSTEOGENESIS; PALPATION; RATS; RATS, INBRED LEW; RECOMBINANT PROTEINS; SPINAL FUSION; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRANSDUCTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 46749155471     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181761003     Document Type: Article

References (29)

1. Silber JS, Anderson DG, Daffner SD, et al. Donor site morbidity after anterior iliac crest bone harvest for single-level anterior cervical discectomy and fusion. Spine 2003;28:134-9.
2. Ahlmann E, Patzakis M, Roidis N, et al. Comparison of anterior and posterior iliac crest bone grafts in terms of harvest-site morbidity and functional outcomes. J Bone Joint Surg Am 2002;84-A:716-20.
3. Gupta MC, Maitra S. Bone grafts and bone morphogenetic proteins in spine fusion. Cell Tissue Bank 2002;3:255-67.
4. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528-34.
5. Dimar JR, Glassman SD, Burkus KJ, et al. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine 2006;31:2534-9.
6. Kanayama M, Hashimoto T, Shigenobu K, et al. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine 2006;31:1067-74.
7. Vaccaro AR, Anderson DG, Patel T, et al. Comparison of OP-1 Putty (rh-BMP-7) to iliac crest autograft for posterolateral lumbar arthrodesis: a minimum 2-year follow-up pilot study. Spine 2005;30:2709-16.
8. Vaccaro AR, Patel T, Fischgrund J, et al. A 2-year follow-up pilot study evaluating the safety and efficacy of op-lputty (rhbmp-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur Spine J 2005;14: 623-9.
9. Perri B, Cooper M, Lauryssen C, et al. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: adiscectomy and fusion: a case study. Spine J 2007;7:235-9.
10. Lieberman JR, Ghivizzani SC, Evans CH. Gene transfer approaches to the healing of bone and cartilage. Mol Ther 2002;6:141-7.
11. Wang JC, Kanim LE, Yoo S, et al. Effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. J Bone Joint Surg Am 2003;85-A:905-11.
12. Zhao J, Zhao DY, Shen AG, et al. Promoting lumbar spinal fusion by adenovirusjmediated bone morphogenetic protein-4 gene therapy. Chin J Traumatol 2007;10:72-6.
13. Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003;13:155-al.
14. Poller W, Fechner H, Noutsias M, et al. Highly variable expression of virus receptors in the human cardiovascular system. Implications for cardiotropic viral infections and gene therapy. Z Kardiol 2002;91:978-91.
15. Vanden Driessche T, Collen D, Chuah MK. Viral vector-mediated gene therapy for hemophilia. Curr Gene Ther 2001;l:301-15.
16. Feeley BT, Conduah AH, Sugiyama O, et al. In vivo molecular imaging of adenoviral versus lentiviral gene therapy in two bone formation models. J Orthop Res 2006;24:1709-21.
17. Sugiyama O, An DS, Kung SP, et al. Lentivirus-mediated gene transfer induces long-term transgene expression of BMP-2 in vitro and new bone formation in vivo. Mol Ther 2005;11:390-8.
18. Yang S, Wei D, Wang D, et al. In vitro and in vivo synergistic interactions between the Runx2/Cbfal transcription factor and bone morphogenetic pro-tein-2 in stimulating osteoblast differentiation. J Bone Miner Res 2003;18: 705-15.
19. Louis-Ugbo J, Kim HS, Boden SD, et al. Retention of 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J Orthop Res 2002;20:1050-9.
20. Mack CA, Song WR, Carpenter H, et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997;8:99-109.
21. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-11.
22. Riew KD, Wright NM, Cheng S, et al. Induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene in a rabbit spinal fusion model. Calcif Tissue Int 1998;63:357-60.
23. Flaitz CM, Hicks MJ. Molecular piracy: the viral link to carcinogenesis. Oral Oncol 1998;34:448-53.
24. Connolly JB. Lentiviruses in gene therapy clinical research. Gene Ther 2002; 9:1730-4.
25. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998;72:8463-71.
26. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998;72:9873-80.
27. Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997;15:871-5.
28. Bai Y, Soda Y, Izawa K, et al. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. Gene Ther 2003;10:1446-57.
29. An DS, Xie Y, Mao SH, et al. Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum Gene Ther 2003;14:1207-12.